【24h】

Natural history of unexplained chronic hepatitis after liver transplantation.

机译:肝移植后无法解释的慢性肝炎的自然病史。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Unexplained chronic hepatitis (CH) in the adult liver allograft recipient is not uncommon, but its natural history and clinical significance is unknown. A retrospective study was undertaken of adult liver allograft recipients to determine the frequency and natural history of unexplained CH. We evaluated only those patients who had undergone >/=2 liver biopsies after 6 months and were grafted for indications where recurrent disease could be confidently excluded (alcoholic liver disease [ALD] in those who remained abstinent and fulminant hepatic failure [FHF] from drug reactions). Of 288 patients who were transplanted for ALD or FHF, 30 fulfilled the above criteria. CH was first diagnosed at a median of 15.25 months after transplantation. A total of 24 patients showed mild necroinflammatory changes, and 12 had mild or moderate fibrosis. Liver tests did not reflect the presence or degree of inflammation or fibrosis. After a median of 4 years, necroinflammatory scores were increased in 5; new or progressive fibrosis was noted in 13%; 3 had developed cirrhosis; and 5 developed clinical evidence of portal hypertension. Progressive fibrosis was associated with a high titer of anti-nuclear antibodies (>1:1600) and a portal tract plasma cell infiltrate. There was a trend for correlation between necroinflammatory activity and fibrosis stage, but this did not reach statistical significance (P = 0.06). Serum alkaline phosphatase (P = 0.012) and female gender of the donor (P = 0.033) were associated with progressive fibrosis. Unexplained CH is not uncommon in the liver allograft and may progress to established cirrhosis in a subgroup of patients transplanted for ALD or FHF. Standard liver tests do not reflect the extent of these changes, so protocol liver biopsies may be required to detect these changes. We recommend careful history and follow-up in these patients. Liver Transpl, 2007. (c) 2007 AASLD.
机译:在成人同种异体肝移植受者中,无法解释的慢性肝炎(CH)并不少见,但其自然病史和临床意义尚不清楚。对成年肝同种异体移植接受者进行了回顾性研究,以确定无法解释的CH的发生频率和自然史。我们仅评估那些在6个月后进行了> / = 2次肝活检的患者,并进行了移植以明确确定可以明确排除复发性疾病的适应症(酒精性肝病[ALD]),这些患者仍然因药物而禁忌和暴发性肝衰竭[FHF]反应)。在288例接受ALD或FHF移植的患者中,有30例符合上述标准。首次在移植后中值15.25个月诊断出CH。共有24例患者出现轻度的坏死性炎症改变,其中12例患有轻度或中度纤维化。肝测试不能反映炎症或纤维化的存在或程度。中位4年后,坏死性炎症评分增加了5;发现新发或进行性纤维化的比例为13%; 3例发展为肝硬化; 5有门脉高压的临床证据。进行性纤维化与高滴度的抗核抗体(> 1:1600)和门脉浆细胞浸润有关。坏死性炎症活动与纤维化分期之间存在相关性趋势,但这没有统计学意义(P = 0.06)。血清碱性磷酸酶(P = 0.012)和供体的女性性别(P = 0.033)与进行性纤维化有关。无法解释的CH在肝同种异体移植中并不罕见,并且可能会在接受ALD或FHF移植的亚组患者中发展为肝硬化。标准的肝脏检查不能反映这些变化的程度,因此可能需要进行协议肝活检以检测这些变化。我们建议对这些患者进行仔细的病史和随访。 Liver Transpl,2007。(c)2007 AASLD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号